USD10
DNTH Shares
About Dianthus TherapeuticsDianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
USD10
DNTH Shares
About Dianthus TherapeuticsDianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$3.35B
OPEN PRICE
$79.63
LOW (1Y)
$13.37
HIGH (1Y)
$88.02
LOW (24H)
$75.80
HIGH (24H)
$82.49
VOLUME (24H)
$2.42M
229.14%
Price history
Time | Price | Change |
|---|---|---|
Today | $79.63 | |
1 Day | $77.76 | |
1 Week | $77.90 | |
1 Month | $51.38 | |
1 Year | $19.41 |